EpilepsyGTx raises $33 million Series A to develop single dose gene therapy for focal refractory epilepsy
EpilepsyGTx, a biotechnology company focused on research and development of cutting-edge gene therapies to treat refractory epilepsy, today announced it has raised $33 million in a Series A financing to…